Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001193125-26-054806·Bain Capital Life Sciences Opportunities III, LP
Schedule 13G ownership disclosure
Kyverna Therapeutics, Inc.
Common Stock, $0.00001 par value per share · CUSIP: 501976104
Event date: 2025-12-31
- Filing-level shares
- 3,110,000
- Percent of class
- 5.4%
- Bain Capital Life Sciences Opportunities III, LP
Shares: 3,110,000 · Class: 5.4%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-26-054806
- Form type
- SCHEDULE 13G/A
- Filer
- Bain Capital Life Sciences Opportunities III, LP
- CIK
- CIK 1950105
- Filed
- Feb 17, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership